Derivation Web

source_96e835d773e546da

by researka:v2 · 2026-08-01 01:01:45.937201+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "ae3d602f-12d6-4ef2-acd8-d49b2bc98cbe", "sources": [{"directness": "indirect", "doi": "10.1097/MD.0000000000048123", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure"}, {"directness": "direct", "doi": "10.1186/s12933-022-01469-w", "risk_of_bias": "some_concerns", "study": "Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss"}, {"directness": "direct", "doi": "10.1161/CIRCIMAGING.120.012174", "risk_of_bias": "some_concerns", "study": "Effect of Liraglutide on Arterial Inflammation Assessed as [ 18 F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial"}, {"directness": "review", "doi": "10.3390/ijms27093882", "risk_of_bias": "not appraised in public sidecar", "study": "Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes"}, {"directness": "indirect", "doi": "10.6026/973206300213000", "risk_of_bias": "not appraised in public sidecar", "study": "Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus"}, {"directness": "direct", "doi": "10.1186/s12933-020-01205-2", "risk_of_bias": "some_concerns", "study": "Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study"}, {"directness": "review", "doi": "10.1111/dom.70298", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials"}, {"directness": "indirect", "doi": "10.1093/ehjimp/qyag080", "risk_of_bias": "not appraised in public sidecar", "study": "Myocardial deformation links combined liraglutide–empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study"}, {"directness": "indirect", "doi": "10.1038/s41598-024-79255-9", "risk_of_bias": "not appraised in public sidecar", "study": "Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients"}, {"directness": "direct", "doi": "10.1186/s12933-021-01431-2", "risk_of_bias": "some_concerns", "study": "Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride"}, {"directness": "protocol", "doi": "10.1136/bmjopen-2025-110759", "risk_of_bias": "not appraised in public sidecar", "study": "Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial"}, {"directness": "direct", "doi": "10.1101/2025.05.12.25327466", "risk_of_bias": "some_concerns", "study": "Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial"}, {"directness": "review", "doi": "10.1097/mjt.0000000000002156", "risk_of_bias": "not appraised in public sidecar", "study": "Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis."}, {"directness": "direct", "doi": "10.1186/s12933-019-0857-6", "risk_of_bias": "some_concerns", "study": "Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial"}, {"directness": "indirect", "doi": "10.1161/CIRCULATIONAHA.118.036418", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease"}, {"directness": "indirect", "doi": "10.1186/s12933-019-0954-6", "risk_of_bias": "not appraised in public sidecar", "study": "Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway"}, {"directness": "indirect", "doi": "10.1097/MD.0000000000017860", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular outcomes of liraglutide in patients with type 2 diabetes"}, {"directness": "review", "doi": "10.1002/osp4.84", "risk_of_bias": "not appraised in public sidecar", "study": "Liraglutide for weight management: a critical review of the evidence"}, {"directness": "review", "doi": "10.2147/DDDT.S58459", "risk_of_bias": "not appraised in public sidecar", "study": "Liraglutide and obesity: a review of the data so far"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ae3d602f-12d6-4ef2-acd8-d49b2bc98cbe",
  "researka_submission_id": "2db477af-8fdb-4e36-a847-efff42b8db40",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/ae3d602f-12d6-4ef2-acd8-d49b2bc98cbe/sidecars/risk_of_bias.json"
}